Is NCT05908331 recruiting in Decatur, GA?

Yes, NCT05908331 is currently recruiting participants at its Decatur, GA location. This in-stent restenosis clinical trial is actively enrolling qualified participants.

How do I join the in-stent restenosis clinical trial in Decatur?

To join this clinical trial in Decatur, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Decatur clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

In-Stent Restenosis Clinical Trial in Decatur, GA

About This In-Stent Restenosis Study in Decatur

A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a maximum of 50 study sites located in the United States. The goal is to establish the safety and efficacy of the MagicTouch™ sirolimus- coated balloon in treatment of coronary in-stent restenosis (ISR).

Sponsor: Concept Medical Inc.

Who Can Participate

Inclusion Criteria

Subject is at least 18 years old

Subject (or legal guardian) understands the trial requirements and treatment procedures and provides written informed consent prior to any trial-specific tests or treatment

Patient with an indication for PCI due to suspected in-stent restenosis

Non-target lesion PCI are allowed in non-target vessels to be treated with approved interventional devices prior to randomization as follows: Angiographic Inclusion Criteria:

In-stent restenosis after drug-eluting stent implantation(s) in the target lesion (i.e. single and multiple stent layer ISR cases are eligible)

Target lesion must have visually estimated stenosis ≥50% and less than 100% diameter stenosis in symptomatic patients; or a visually estimated target lesion diameter stenosis of ≥70%, or by evidence of ischemia by coronary physiology (fractional flow reserve \[FFR\] ≤0.80 or non-hyperemic pressure ratio \[NHPR\] ≤0.89) in absence of symptoms

Successful lesion preparation (residual stenosis \<30%), without complications (no or slow flow, flow-limiting dissection, perforation, distal embolization) and without plan for stenting

Target lesion in a native coronary artery

Thrombolysis In Myocardial Infartction (TIMI) grade flow ≥1 in target lesion

Target reference vessel diameter (visual estimation) \>2.0 and ≤4.0 mm

Target lesion length (including tandem lesions) ≤36.0 mm (visual estimation) and can be covered by only one balloon

One ISR target lesion (overlapping stents are allowed) to be treated per patient and in single major coronary artery or side branch (reference vessel diameter \>2.0 mm)

Other coronary lesions (ISR or non-ISR) in non-target vessel are allowed and may be treated by any approved interventional device, but must be treated successfully prior to randomization

Exclusion Criteria

General Exclusion Criteria (all must be absent for the patient to be eligible):

STEMI within 72 hours of presentation to the first treating hospital, whether a transfer facility or the study hospital

NSTEACS in whom the biomarkers have not peaked

PCI within the 24 hours prior to the index procedure (not including PCI performed in non-target lesions during the index procedure)

Prior DCB treatment (coronary or off-label peripheral) of target lesion ISR

Cardiogenic shock (defined as persistent hypotension \[systolic blood pressure \<90 mm Hg\] or requiring vasoactive or hemodynamic support, including IABP)

Subject is intubated

Known left ventricular ejection fraction \<30%

Relative or absolute contraindication to DAPT for at least 1 month (e.g., planned surgeries that cannot be delayed)

Subject has an indication for chronic oral anticoagulation treatment and a contraindication for concomitant treatment with a P2Y12 inhibitor

If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath

Hemoglobin \<9 g/dL

Platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3

White blood cell count \<3,000 cells/mm3

Active infection undergoing treatment

Clinically significant liver disease

Renal insufficiency as defined by estimated glomerular filtration rate (eGFR) to be \<30ml/min by the MDRD formula

Active peptic ulcer or active bleeding from any site

Bleeding from any site requiring active medical attention within the prior 8 weeks

History of bleeding diathesis or coagulopathy or likely to refuse blood transfusions

Cerebrovascular accident (CVA) within 3 months or has any permanent neurological defect as a result of CVA

Known allergy to the study device components or protocol-required concomitant medications: \- sirolimus (as well as other limus drugs, analogues, or similar compounds), aspirin, clopidogrel and prasugrel and ticagrelor, heparin and bivalirudin, or iodinated contrast that cannot be adequately pre-medicated

Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.) or reduce life expectancy to \<24 months (e.g. cancer, heart failure, lung disease, severe valvular disease)

Patient is participating in or plans to participate in any other investigational drug or device trial that has not reached its primary endpoint

Women who are pregnant or breastfeeding (women of child-bearing potential must have a negative pregnancy test within one week before index procedure)

Women who intend to become pregnant within 12 months after the index procedure

Patient has received an organ transplant or is on a waiting list for an organ transplant

Patient has received chemotherapy within 30 days before the index procedure or scheduled to receive chemotherapy any time after the index procedure

Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease. Inhaled steroid and steroid use for contrast- allergy prophylaxis or treatment are allowed Angiographic Exclusion Criteria (visual estimate) (all must be absent for the patient to be eligible):

More than 1 ISR lesion in the target vessel in segments that cannot be treated by a single 40mm length DCB (see Angiographic Inclusions #5 and #6 above)

ISR lesion in the target vessel in a segment that corresponds to a previously established/documented bare metal stent (BMS)

Unprotected left main lesions \>50% or left main intervention

Primary PCI for STEMI

Coronary artery disease judged more suitable for surgical revascularization per guidelines and local heart team discussion

Another lesion in either the target vessel or non-target vessel is present that requires or has a high probability of requiring PCI within 12 months after the index procedure

Prior brachytherapy or DCB treatment of target lesion

Target lesion is a bifurcation restenosis involving both branches of a bifurcation in which the side branch reference vessel diameter is \>2.0 mm

Target lesions located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft

Target lesion contains large thrombus

Target lesion is heavily calcified

Target lesion is a chronic total occlusion (or subtotal) without adequate lesion preparation.\

Total and subtotal occlusions may be enrolled assuming they can be crossed with a wire and demonstrate TIMI grade 3 flow at the time of randomization.

Diffuse distal disease to target lesion with impaired runoff

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Decatur?

Yes, this clinical trial (NCT05908331) has an active research site in Decatur, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

In-Stent Restenosis Treatment Options in Decatur, GA

If you're searching for in-stent restenosis treatment options in Decatur, GA, this clinical trial (NCT05908331) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Decatur research site is actively enrolling participants for this clinical trial. You'll receive care from experienced in-stent restenosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

In-Stent Restenosis Clinical Trial in Decatur, GA

Expert Care in Decatur

IRB Approved

No-Cost Care

Apply for This Decatur Location

Why Participate?

Simple Process